WILEX WKN: A11QVV ISIN: DE000A11QVV0 Kürzel: HPHA Forum: Aktien Thema: Hauptdiskussion

Da geht schon lange nichts mehr was ist da los bei 5;80 eingestiegen 🥵

Sehe ich nicht so, dafür steht zu viel an: Telix wird Planmäßig die Rekrutierung der Phase 3 Studie bis Ende des Jahres abschließen für TLX250 HDP hat Portfolio mit HDP-102 und HDP-103 erweitert (deshalb auch die höheren Aufwendungen. Das wäre nicht passiert wenn es mit HDP-101 Probleme geben würde. HDP-101 soll nächstes Jahr ebenfalls in die klinischen Studien gehen. Es gab kürzlich eine Präsentation mit entsprechender time -line Das Covid-19 Medikament von RedHill ist ebenfalls noch im Rennen. Hierzu könnte es auch bis Ende des Jahres noch News geben Von Seitens Magenta sind ebenfalls News zu erwarten Schaut man sich die Handelsumsätze der letzten Zeit an, ist das gering. Sollten hier positive News der Studien kommen, können wir ganz schnell wieder bei 5 und mehr sein...

Ja ob das nochmal auf 5 € steigt fraglich

Nur nach unten

Findest immer noch?

Eine beruhigende Bewegung letzte Zeit.🙏🏽

Der Herr Hopp hat mit Biotechnologie auch schon viel Geld verloren haben. Es tut ihm aber nicht so weh wie einem Kleinanleger.

Geduld wird sich hier auszahlen...habe meine Position Ende 2016 angefangen aufzubauen...Geduld ist gefragt aber wenn die Ernte reich ausfällt passt das...Die Saat ist ausgeworfen und eine reife Frucht braucht ihre Zeit 😎

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16271

...und hier die nächste Meldung wo wir auch dabei sind 👍😎 RHB-107 ist ebenfalls von HDP... TEL-AVIV, Israel and RALEIGH, N.C., July 1, 2020 RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 development programs with opaganib (Yeliva®, ABC294640)1 and RHB-107 (upamostat, WX-671)2 for COVID-19 at the Sachs Digital Novel Coronavirus Investment Forum, taking place July 7-9, 2020. About RHB-107 (upamostat) RHB-107 is a proprietary, first-in-class, orally administered potent inhibitor of several serine proteases targeting cancer, inflammatory lung diseases, and gastrointestinal diseases. RedHill is currently pursuing a Phase 2/3 clinical development program with RHB-107 for COVID-19. RHB-107 has undergone several Phase 1 studies and two Phase 2 proof-of-concept studies demonstrating its clinical safety profile in over 300 patients across 10 clinical studies, including two completed Phase 2 studies in oncology patients and several Phase 1 studies in healthy volunteers and oncology patients. These studies helped establish the safety and tolerability of RHB-107 in humans. RedHill acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan, and Macao, from Germany’s Heidelberg Pharmaceuticals (formerly WILEX AG) for all indications.

Die habe ich.. Wenn ich mal meditation mache, komme I h immer hier her😎

Ledako, Ausdauer ist bei der Aktie gefragt...😅

Na endlich mal ne Meldung! Die Aktie liegt bei mir so rum... Der hopp wird schon wissen, was er mit seinem Geld macht. @ Goldfisch: Danke für den post

Partner Telix hat ein den nächsten Meilenstein eines von HDP (damals noch Wilex) auslizenziertes Produkt (mit hohem Potenzial; was sowohl für Diagnostik als auch für Therapie eingesetzt werden kann) erreicht: Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product TLX250-CDx

https://www.boersennews.de/nachrichten/artikel/DGAP-News:-Heidelberg-Pharma-pr%C3%A4sentiert-auf-dem-kommenden-virtuellen-European-Biotech-Investor-Day-2020-(deutsch)/2344980/

HDP profitiert maximal durch mehr Bekanntheit/Aufmerksamkeit da Hopp an beiden Unternehmen stark beteiligt ist. Wer ernsthaft an HDP interessiert ist sollte auch den Newsflow der Partnerunternehmen wie bspw. Magenta verfolgen. Hier kamen in letzter Zeit sehr gute News im Hinblick auf die von HDP weiterentwickelten Molekühle. Leider ist die PR von HDP noch nicht so gut dass die Infos direkt von HDP publiziert werden. Ich schätze wenn dann die großen News von HDP kommen wird die Aktie stark ansteigen, da viele die Entwicklung nicht bekommen haben die auch durch die Partner stattgefunden haben. Hier die aktuellste News die von Magenta heute rausgegangen ist: MAGENTA THERAPEUTICS AND BEAM THERAPEUTICS ANNOUNCE COLLABORATION TO EVALUATE TARGETED ANTIBODY-DRUG CONJUGATE (ADC) MGTA-117 AS CONDITIONING REGIMEN FOR BASE EDITING THERAPIES June 15, 2020 Download PDF – MGTA-117 conditioning for precise depletion of cells in the bone marrow could potentially increase patients’ benefit from Beam’s base editing therapies for sickle cell disease and beta thalassemia – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2020-- Magenta Therapeutics (Nasdaq: MGTA) and Beam Therapeutics (Nasdaq: BEAM) today announced a non-exclusive research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted ADC for conditioning of patients with sickle cell disease and beta-thalassemia receiving Beam’s base editing therapies. Beam is pursuing two differentiated base editing approaches to treat hemoglobinopathies: its hereditary persistence of fetal hemoglobin (HPFH) program to precisely and robustly elevate fetal hemoglobin, which could be used in treatments for both sickle cell disease and beta-thalassemia, as well as a novel approach to directly correct the sickle causing point mutation (Makassar). Conditioning is a critical component necessary to prepare a patient’s body to receive the edited cells, which carry the corrected gene and must engraft in the patient’s bone marrow in order to be effective. Today’s conditioning regimens rely on nonspecific chemotherapy or radiation, which are associated with significant toxicities. MGTA-117 precisely targets only hematopoietic stem and progenitor cells, sparing immune cells, and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models. MGTA-117 may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Beam has demonstrated the ability to edit individual DNA bases in hematopoietic stem cells at high efficiency and with little impact on the viability of edited cells relative to unedited cells using its novel base editing technology. Combining MGTA-117 with Beam’s HPFH and Makassar base editors could meaningfully advance the treatment of patients with sickle cell disease or beta-thalassemia. “We believe patients will benefit from a more precise process to remove hematopoietic stem cells and prepare them to receive genetic medicines. Magenta has developed targeted ADCs as the preferred modality for our conditioning programs, and we have designed MGTA-117 specifically to optimize it for use with a genetically-modified cell product delivered in a transplant setting,” said Jason Gardner, D.Phil., president and chief executive officer, Magenta Therapeutics. “Beam’s next-generation base editing technology complements our next-generation conditioning approach very well, and we are excited to combine these strengths to address the still-significant unmet medical needs of the sickle cell and beta-thalassemia patient communities.” “Base editing has the potential to offer lifelong treatment for patients with many diseases, including sickle cell disease and beta-thalassemia. Our novel base editors create precise single base changes in genes without cutting the DNA, enabling durable correction of hematopoietic stem cells with minimal effects on cell viability or genomic integrity,” said John Evans, chief executive officer of Beam. “Combining the precision of our base editing technology with the more targeted conditioning regimen enabled by MGTA-117 could further improve therapeutic outcomes for patients suffering from these severe diseases. We look forward to partnering with the Magenta team to explore these novel technologies together.” Beam will be responsible for clinical trial costs related to development of Beam’s base editors when combined with MGTA-117, while Magenta will continue to be responsible for all other development costs of MGTA-117. Magenta will also continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases. Each company will retain all commercial rights to their respective technologies. About MGTA-117 MGTA-117, Magenta’s most advanced conditioning program, is a CD117-targeted antibody engineered for the transplant setting and conjugated to amanitin, a toxin in-licensed from Heidelberg Pharma. It is designed to precisely deplete only hematopoietic stem and progenitor cells and has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models, suggesting that it may be capable of clearing space in bone marrow to support long-term engraftment and rapid recovery in patients. Magenta plans to complete IND-enabling studies this year and initiate clinical studies in 2021. Magenta will continue to develop MGTA-117 in other diseases, including blood cancers and genetic diseases.